A comprehensive review on metabolic syndrome

Kaur, Jaspinder·2014·Cardiology Research and Practice
DOI 10.1155/2014/943162

Cites (249)

Items 201–249 of 249

  1. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome
    Jonathan E. Shaw, Donald J. Chisholm · 2003 · The Medical Journal of Australia
  2. Hypertension and the Metabolic Syndrome
    Stephen A Morse, Rubin Zhang, Vashu Thakur, Efrain Reisin · 2005 · The American Journal of the Medical Sciences
  3. Cardiovascular effects of leptin and orexins
    Tetsuro Shirasaka, Mayumi Takasaki, Hiroshi Kannan · 2003 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  4. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: The InChianti study
    Giovanni Zuliani, Stefano Volpato, Blé A, Stefania Bandinelli, Anna Maria Corsi, Fulvio Lauretani, Giuseppe Paolisso, R. Fellin, Luigi Ferrucci · 2006 · Atherosclerosis
  5. The Key Role of Insulin Resistance in the Cardiometabolic Syndrome
    Harvinder Gill, Maryann N. Mugo, Adam T. Whaley‐Connell, Craig S. Stump, James R. Sowers · 2005 · The American Journal of the Medical Sciences
  6. Glucocorticoid metabolism and the Metabolic Syndrome: associations in an elderly cohort
    Ruth Andrew, Catharine R. Galé, Brian Robert Walker, Jonathan R. Seckl, Christopher N Martyn · 2002 · Experimental and Clinical Endocrinology & Diabetes
  7. Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome
    Leslie Landaeta‐Díaz, JM Fernández, Marzo Edir Da Silva‐Grigoletto, Daniel Rosado-Álvarez, Angela Gomez-Garduño, Francisco Gómez-Delgado, José López‐Miranda, Francisco Pérez‐Jiménez, Francisco J. Fuentes · 2012 · European Journal of Preventive Cardiology
  8. Functional foods and physical activities in health promotion of aging people
    Carlos Kusano Bucalen Ferrari · 2007 · Maturitas
  9. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
    Rebecca Bakker‐Arkema · 1996 · JAMA
  10. Obesity, Hypertension, and Insulin Resistance
    Zachary T. Bloomgarden · 2002 · Diabetes Care
  11. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein
    Sibel Güldiken, Muzaffer Demir, Ender Arıkan, Burhan Turgut, Şennur Azcan, Murat Gerenli, Armağan Tuğrul · 2006 · Thrombosis Research
  12. Metabolic syndrome and skin: Psoriasis and beyond
    Tanmay Padhi, Garima · 2013 · Indian Journal of Dermatology
  13. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome
    Jonathan E. Shaw, Donald J. Chisholm · 2003 · The Medical Journal of Australia
  14. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
    Edward J. Mills, Jonathan E. Prousky, Gannady Raskin, Joel Joseph Gagnier, Beth Rachlis, Víctor M. Montori, David Nelson Juurlink · 2003 · BMC Clinical Pharmacology
  15. Effects of Dexamethasone on the Synthesis, Degradation, and Secretion of Apolipoprotein B in Cultured Rat Hepatocytes
    Chuen‐Neu Wang, Roger S. McLeod, Zemin Yao, David N. Brindley · 1995 · Arteriosclerosis Thrombosis and Vascular Biology
  16. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin
    Donald B. Hunninghake, Mark E. McGovern, Michael J. Koren, Ronald Brazg, David K. Murdock, Stuart R. Weiss, Thomas A. Pearson · 2003 · Clinical Cardiology
  17. Metabolic Syndrome and Incident Cardiovascular Morbidity and Mortality in a Mediterranean Hypertensive Population
    Emmanouil Andreadis, George I. Tsourous, Chara K. Tzavara · 2007 · American Journal of Hypertension
  18. Introduction
    2005 · Diabetes Care
  19. Contribution of PAI-1 in cardiovascular pathology.
    Marie‐Christine Alessi, Irène Juhan-Vague · 2004 · PubMed
  20. Supplement 1. American Diabetes Association: clinical practice recommendations 2000.
    2000 · PubMed
  21. The ALLHAT Lipid Lowering Trial—Less Is Less
    Richard C. Pasternak · 2002 · JAMA
  22. Metabolic Syndrome: Treatment of Hypertensive Patients
    Zafar H. Israili, Badiaâ Lyoussi, Rafael Hernández-Hernández, Manuel Velasco · 2007 · American Journal of Therapeutics
  23. Sleep & the metabolic syndrome.
    Jamie Lam, Msm Ip · 2010 · PubMed
  24. Erratum
    2002 · Diabetes Care
  25. The Intestinal Absorption of Biliary and Dietary Cholesterol as a Drug Target for Lowering the Plasma Cholesterol Level
    Stephen D. Turley, John M. Dietschy · 2003 · Preventive Cardiology
  26. Two measures of insulin sensitivity provided similar information in a U.S. population
    Dawn M. Bravata, Carolyn K. Wells, John Concato, Walter N. Kernan, Lawrence M. Brass, Barbara Gulanski · 2004 · Journal of Clinical Epidemiology
  27. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study
    D. A. Leaf · 1989 · JAMA
  28. Gene variants, insulin resistance, and dyslipidaemia
    Laakso, Markku · 2004 · Current Opinion in Lipidology
  29. Beneficial responses to modified diets in treating patients with chronic kidney disease
    William E. Mitch · 2005 · Kidney International
  30. The Protective Role of the Mediterranean Diet on the Prevalence of Metabolic Syndrome in a Population of Greek Obese Subjects
    Konstantinos Paletas, Eleni A. Athanasiadou, Maria Sarigianni, Paschalis Paschos, Aikaterini Kalogirou, Maria N. Hassapidou, Απόστολος Τσάπας · 2010 · Journal of the American College of Nutrition
  31. Aetiology and consequences of the metabolic syndrome
    Eberhard Standl · 2005 · European Heart Journal Supplements
  32. Lifestyle Modification in the Management of Obesity
    Thomas A. Wadden, Brian G. McGuckin, Rebecca A. Rothman, Stephanie Lee Sargent · 2003 · Journal of Gastrointestinal Surgery
  33. Metabolic Syndrome Pathophysiology and Clinical Presentation
    Yehuda Handelsman · 2008 · Toxicologic Pathology
  34. Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion
    Jonathan E. Shaw, Paul Zimmet, K. G. M. M. Alberti · 2006 · Diabetes Care
  35. Metabolic Aspects of Bariatric Surgery
    Franco B. Folli, Antonio Ettore Pontiroli, Wayne H. Schwesinger · 2007 · Medical Clinics of North America
  36. Phenotypic, genetic, and genome-wide structure in the metabolic syndrome
    Martin, Lisa J, North, Kari E, Dyer, Tom, Blangero, John, Comuzzie, Anthony G, Williams, Jeff · 2003 · BMC Genetics
  37. Genetic links between diabetes mellitus and coronary atherosclerosis
    José María Ordovás · 2007 · Current Atherosclerosis Reports
  38. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials
    Rukmini Rajagopalan, Shrividya S. Iyer, Mehmood A. Khan · 2005 · Current Medical Research and Opinion
  39. Metabolic benefits associated with sibutramine therapy
    G. J. Krejs · 2002 · International Journal of Obesity
  40. Fibrates in the metabolic syndrome and in diabetes
    George A. Steiner · 2004 · Endocrinology and Metabolism Clinics of North America
  41. Ocular associations of metabolic syndrome
    Jubbin Jagan Jacob, Rupali Chopra, Ashish Chander · 2012 · Indian Journal of Endocrinology and Metabolism
  42. Intensified Screening and Treatment of the Metabolic Syndrome for Cardiovascular Risk Reduction
    Nathan D. Wong · 2005 · Preventive Cardiology
  43. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers—a gap in evidence-based medicine
    Stephen G. Ball, William B. White · 2003 · The American Journal of Cardiology
  44. Adiponectin represents an independent risk factor for hypertension in middle aged Korean women.
    Hyun‐Sook Lee, Myoungsook Lee, Hyojee Joung · 2007 · PubMed
  45. Management of metabolic syndrome: aspirin
    T.Matthew Shields, Charles H. Hennekens · 2004 · Endocrinology and Metabolism Clinics of North America
  46. Combination therapy for the treatment of dyslipidemia.
    Dan A. Streja · 2004 · PubMed
  47. Glucocorticoid-Induced Insulin ResistanceIn Vitro:Inhibition of Insulin-Stimulated Methylaminoisobutyric Acid Uptake
    Carl Grünfeld, Debra Jones · 1986 · Hormone and Metabolic Research
  48. Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion
    J. E. Shaw · 2006 · Diabetes Care
  49. Untitled work
    Alberti · 1998 · 10.1002/(sici)1096-9136(199807)15:7